Nursing Considerations with EGFR Inhibitors in NSCLC

While there has been significant progress in the treatments for lung cancer over the past decade, it remains the leading cause of cancer death as of 2019. The discovery of the epidermal growth factor receptor (EGFR) mutation in lung cancer cells has led to treatments with EGFR inhibitors which have yielded results superior to chemotherapy in patients who harbor this mutation. Toxicities with EGFR inhibitors are very different than standard chemotherapy but can be managed with the proper evaluation and treatment.